JMM Profile: Carbapenems: a broad-spectrum antibiotic: This article is part of the JMM Profiles collection.

Tom Armstrong; Samuel Jacob Fenn; Kim R. Hardie

doi:10.1099/jmm.0.001462

Volume 70, Issue 12

Review Article

Open Access

JMM Profile: Carbapenems: a broad-spectrum antibiotic

This article is part of the JMM Profiles collection.

Tom Armstrong¹, Samuel Jacob Fenn² and Kim R. Hardie²
View Affiliations Hide Affiliations

Affiliations: ¹ School of Chemistry, Biodiscovery Institute, University Park, Nottingham University, Nottingham, NG7 2RD, UK ² School of Life Sciences and National Biofilm Innovation Centre, Biodiscovery Institute, University Park, Nottingham University, Nottingham, NG7 2RD, UK
*Correspondence: Kim R. Hardie, [email protected]
Published: 10 December 2021 https://doi.org/10.1099/jmm.0.001462

Abstract

Carbapenems are potent members of the β-lactam family that inhibit bacterial cell-wall biosynthesis inhibitors . They are highly effective against Gram-negative and Gram-positive drug-resistant infections . As such, carbapenems are typically reserved as an antibiotic of last resort. The WHO lists meropenem as an essential medicine. Nausea and vomiting are reported in ≤20% of carbapenem recipients, with 1.5% suffering seizures. Enzymatic hydrolysis of the β-lactam ring is the main driver of clinical resistance. These enzymes can be classified as Class A, B and D. Classes A and D are serine β-lactamases, whereas Class B rely on metal-mediated hydrolysis, typically through zinc.

Received: 06/05/2021
Accepted: 13/10/2021
Published Online: 10/12/2021

Keyword(s): antimicrobial resistance , last resort and β-lactams

Funding

This study was supported by the:

Wellcome Trust (Award 108876/Z/15/Z)
- Principle Award Recipient: SamuelJacob Fenn
Wellcome Trust (Award 108876/Z/15/Z)
- Principle Award Recipient: TomArmstrong

This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001462

2021-12-10

2024-04-19

Full text loading...

/deliver/fulltext/jmm/70/12/jmm001462.html?itemId=/content/journal/jmm/10.1099/jmm.0.001462&mimeType=html&fmt=ahah

References

Kahan JS, Kahan FM, Goegelman R, Currie SA, Jackson M et al. Thienamycin, a new beta-lactam antibiotic. i. discovery, taxonomy, isolation and physical properties. J Antibiot 1979; 32:1–12 [View Article]
[Google Scholar]
Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrob Agents Chemother 2011; 55:4943–4960 [View Article]
[Google Scholar]
Trebosc V, Schellhorn B, Schill J, Lucchini V, Bühler J et al. In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms. J Antimicrob Chemother 2020; 75:3552–3562 [View Article] [PubMed]
[Google Scholar]
Yocum RR, Rasmussen JR, Strominger JL. The mechanism of action of penicillin. Penicillin acylates the active site of Bacillus stearothermophilus D-alanine carboxypeptidase. J Biol Chem 1980; 255:3977–3986 [PubMed]
[Google Scholar]
Codjoe FS, Donkor ES. Carbapenem resistance: a review. Medical Sciences 2017; 6:1 [View Article]
[Google Scholar]
Meletis G, Vavatsi N, Exindari M, Protonotariou E, Sianou E et al. Accumulation of carbapenem resistance mechanisms in VIM-2-producing Pseudomonas aeruginosa under selective pressure. Eur J Clin Microbiol Infect Dis 2014; 33:253–258 [View Article] [PubMed]
[Google Scholar]
Pitout JD, Nordmann P, Poirel L. Carbapenemase-producing klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chem 2015; 59:5873–5884 [View Article]
[Google Scholar]
Dubée V, Triboulet S, Mainardi J-L, Ethève-Quelquejeu M, Gutmann L et al. Inactivation of mycobacterium tuberculosis l,d-transpeptidase ldtmt₁ by carbapenems and cephalosporins. Antimicrob Agents Chem 2012; 56:4189–4195 [View Article]
[Google Scholar]
Sutter R, Rüegg S, Tschudin-Sutter S. Seizures as adverse events of antibiotic drugs: A systematic review. Neurology 2015; 85:1332–1341 [View Article] [PubMed]
[Google Scholar]

http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001462

JMM Profile: Carbapenems: a broad-spectrum antibiotic

J. Med. Microbiol. 70, 001462 (2021); https://doi.org/10.1099/jmm.0.001462

/content/journal/jmm/10.1099/jmm.0.001462

Data & Media loading...

Volume 70, Issue 12

Review Article

Open Access

JMM Profile: Carbapenems: a broad-spectrum antibiotic

This article is part of the JMM Profiles collection.

Abstract

Funding

Most read this month

Most cited Most Cited RSS feed

Healthcare-associated infections, medical devices and biofilms: risk, tolerance and control

Emerging tick-borne pathogens of public health importance: a mini-review

Differences between the gut microflora of children with autistic spectrum disorders and that of healthy children

Pseudomonas aeruginosa – a phenomenon of bacterial resistance

Evaluation of metal-based antimicrobial compounds for the treatment of bacterial pathogens

The role of Akkermansia muciniphila in obesity, diabetes and atherosclerosis

The Microbial Ecology of the Large Bowel of Breastfed and Formula-fed Infants During the First Year of Life

Microcolony formation: a novel biofilm model of Pseudomonas aeruginosa for the cystic fibrosis lung

Pseudomonas aeruginosa and microbial keratitis

Mechanisms of ciprofloxacin resistance in Pseudomonas aeruginosa: new approaches to an old problem